{"product_id":"gmab-ansoff-analysis","title":"(GMAB) Genmab A\/S ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Genmab A\/S Ansoff Matrix Analysis shows, in one clear matrix, growth options across market penetration, market development, product development, and diversification and is built for strategy, investment, or research use; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX hematology share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX is already a core drug in hematology-oncology, with 2024 sales of $11.7 billion and approved use in multiple myeloma and AL amyloidosis. For Genmab A\/S, market penetration means driving deeper use in the same specialist base and treatment pathways, not adding new buyers. More label wins strengthen brand share and repeat prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeprotumumab thyroid eye disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeprotumumab supports market penetration by deepening use in thyroid eye disease, a defined specialty market. In the pivotal trial, 83% of patients met the proptosis response endpoint versus 10% on placebo, which helps drive adoption in endocrinology and ophthalmology care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOfatumumab CLL and MS base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOfatumumab already serves two established pools: chronic lymphocytic leukemia and relapsing multiple sclerosis, with MS affecting about 2.9 million people worldwide and CLL one of the most common adult leukemias. The market penetration play is to keep prescribers and patients on the same product in current settings, so repeat use can deepen without new launch risk. That supports steady refill demand and lowers acquisition cost versus building a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmivantamab oncology franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmivantamab broadens Genmab A\/S reach inside the same oncology referral network, where NSCLC already drives the main use case and upper-GI expansion can add more high-value visits. In 2025, Rybrevant franchise demand stayed a key growth engine for Johnson \u0026amp; Johnson, with NSCLC being a large, biomarker-led market; the strategy is to convert more of the same lung and GI specialists, not chase new channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame doctors, more tumor types.\u003c\/li\u003e\n\u003cli\u003eNSCLC anchors the franchise.\u003c\/li\u003e\n\u003cli\u003eUpper-GI adds share potential.\u003c\/li\u003e\n\u003cli\u003eMore usage per referral network.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTisotumab vedotin gynecologic oncology base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTisotumab vedotin already has a gynecologic oncology base in cervical cancer and is being pushed into ovarian and other solid tumors, which keeps it close to the same specialist prescribers. In market-penetration terms, the upside is deeper use inside a defined oncologist pool, not a new buyer group.\u003c\/p\u003e\n\u003cp\u003eThis is a practical fit for Genmab A\/S because cervical, ovarian, and related gynecologic settings share referral paths, infusion sites, and toxicity-management needs. The company can build share by widening line-of-use, raising repeat use, and strengthening guideline and real-world adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBase: gynecologic oncology specialists\u003c\/li\u003e\n\u003cli\u003eExpansion: adjacent solid tumor practice\u003c\/li\u003e\n\u003cli\u003eLogic: same prescriber network\u003c\/li\u003e\n\u003cli\u003eGoal: deeper share, not new market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab Grows by Deepening Share in Specialist Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S market penetration is about taking more share from the same specialist base, not finding new buyers. DARZALEX led with $11.7 billion in 2024 sales, while teprotumumab posted an 83% proptosis response in trial data, supporting deeper use in existing care paths.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003ePenetration signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX\u003c\/td\u003e\n\u003ctd\u003e$11.7B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeprotumumab\u003c\/td\u003e\n\u003ctd\u003e83% response\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOfatumumab and amivantamab also fit the same play: more use in CLL, MS, NSCLC, and upper-GI care, with repeat prescribing and guideline wins driving share.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Genmab A\/S’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Genmab A\/S Ansoff Matrix to quickly identify growth opportunities and simplify strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary, peer-reviewed, regulatory, and corporate sources to validate Genmab Ansoff growth paths and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX non-MM expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX's move beyond multiple myeloma into AL amyloidosis and other non-MM blood cancers is classic market development: the same brand serves new disease segments. Johnson \u0026amp; Johnson reported more than $11 billion in DARZALEX sales in the latest year, showing how large the expanded pool already is. That wider label lifts Genmab A\/S's royalty base without needing a new drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOfatumumab from CLL to MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOfatumumab already spans CLL and multiple sclerosis, so Genmab A\/S has turned one antibody into a true new-market move. MS affects about 2.9 million people worldwide, which widens the specialist base far beyond hematology and into neurology and autoimmunity. That shift also supports broader partner-led revenue, with Novartis reporting multi-billion-franc annual Kesimpta sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmivantamab NSCLC to GI cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmivantamab’s move from NSCLC into advanced or metastatic gastric and esophageal cancer is a clear market development step, opening a new solid-tumor segment. Globally, gastric cancer caused about 968,000 new cases and esophageal cancer about 511,000 in 2022, so the GI opportunity is large. For Genmab A\/S, this broadens the asset beyond lung oncology and deepens the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTisotumab vedotin beyond cervical cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTisotumab vedotin (Tivdak) began in cervical cancer, where innovaTV 301 showed median overall survival of 11.5 months versus 9.5 months for chemotherapy. Genmab and Pfizer are now testing it in ovarian and other solid tumors, so this is market development for an existing asset. It expands one ADC into more oncology niches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting asset, new tumor types\u003c\/li\u003e\n\u003cli\u003eBroader solid-tumor reach\u003c\/li\u003e\n\u003cli\u003eBuilt on cervical-cancer data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTeprotumumab specialty eye care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeprotumumab is already commercialized for thyroid eye disease, so this move fits Genmab A\/S as a specialty non-oncology market entry into ophthalmology and endocrine care. The regimen is 8 infusions over 24 weeks, which gives Genmab a clear use case in a high-touch specialist setting.\u003c\/p\u003e\n\u003cp\u003eThat matters because thyroid eye disease is rare but serious, and treatment sits with ophthalmologists and endocrinologists rather than broad primary care. One clean takeaway: Genmab A\/S is not just adding a drug, it is opening a new specialty channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty non-oncology market\u003c\/li\u003e\n\u003cli\u003eOphthalmology and endocrine entry\u003c\/li\u003e\n\u003cli\u003e8 infusions over 24 weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s Growth Play: Expanding Proven Antibodies Into New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S’s market development is about taking proven antibodies into new disease areas, not new science. DARZALEX now reaches beyond multiple myeloma, Kesimpta expanded into neurology, and amivantamab and Tivdak are moving into new solid-tumor settings. Teprotumumab adds a rare non-oncology entry in thyroid eye disease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX\u003c\/td\u003e\n\u003ctd\u003eAL amyloidosis\u003c\/td\u003e\n\u003ctd\u003eJ\u0026amp;J sales above $11bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKesimpta\u003c\/td\u003e\n\u003ctd\u003eMS\u003c\/td\u003e\n\u003ctd\u003e~2.9m people worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmivantamab\u003c\/td\u003e\n\u003ctd\u003eGI cancers\u003c\/td\u003e\n\u003ctd\u003e968k gastric, 511k esophageal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGenmab A\/S Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpcoritamab B-cell malignancies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpcoritamab extends Genmab A\/S into a new product lane within existing hematology-oncology markets, targeting relapsed or refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. As a CD3xCD20 bispecific antibody, it adds another antibody-based option in B-cell cancers and fits the Product Development move in the Ansoff Matrix. In 2025, EPKINLY was already a commercial oncology asset, so this pipeline can deepen Genmab A\/S’s immune-oncology reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEN1047 solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGEN1047 is Genmab A\/S product development in solid tumors, so it is a new offer in the company’s core oncology market. Solid tumors account for about 90% of adult cancers, which gives this pipeline asset a large target pool. It supports Genmab’s 2025\/2026 push to grow inside oncology rather than move into a new field.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuoBody-PD-L1x4-1BB solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDuoBody-PD-L1x4-1BB is Genmab A\/S's solid-tumor program in immuno-oncology, using a PD-L1x4-1BB bispecific design to add a differentiated mechanism to an existing cancer market. This fits product development in the Ansoff Matrix, not new-market entry. Genmab reported 2025 revenue of DKK 29.4 billion and R\u0026amp;D spend of DKK 9.2 billion, showing the scale behind this bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDuoBody-CD40x4-1BB solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDuoBody-CD40x4-1BB is a solid-tumor program that pushes Genmab A\/S beyond its current cancer assets by using the DuoBody platform to pair CD40 and 4-1BB, two immune targets, in one bispecific antibody. This supports product renewal in oncology and broadens the Company Name’s pipeline beyond its marketed revenue base. \u003c\/p\u003e\n\u003cp\u003eFor Genmab A\/S, the strategic value is clear: more shots in solid tumors, where success can scale fast if clinical data hold. The program fits an Ansoff \"product development\" move because it sells new oncology products to the same core cancer market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo-target design: CD40 plus 4-1BB\u003c\/li\u003e\n\u003cli\u003eFocus: solid tumors\u003c\/li\u003e\n\u003cli\u003eRole: pipeline renewal in oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHexaBody-CD38 and DuoHexaBody-CD37\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHexaBody-CD38 and DuoHexaBody-CD37 are both hematological-malignancy programs, so they fit Genmab A\/S product development: new antibody assets built on its core oncology base. This extends the blood-cancer portfolio with next-generation CD38 and CD37 biology, rather than moving into a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eTargets blood cancers only\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAdds next-gen antibody assets\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBuilds on oncology know-how\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProduct development, not market entry\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab Doubles Down on Oncology Pipeline Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S uses Product Development to add new oncology assets to its core cancer markets, led by EPKINLY, GEN1047, and DuoBody bispecifics in solid tumors and blood cancers. In 2025, Genmab A\/S reported revenue of DKK 29.4 billion and R\u0026amp;D of DKK 9.2 billion, supporting this pipeline push. The strategy deepens share in oncology, not new-market entry.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPKINLY\u003c\/td\u003e\n\u003ctd\u003eBlood cancers\u003c\/td\u003e\n\u003ctd\u003eNew product, same market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGEN1047\u003c\/td\u003e\n\u003ctd\u003eSolid tumors\u003c\/td\u003e\n\u003ctd\u003eNew product, same oncology base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuoBody bispecifics\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003ePipeline renewal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePRV-015 celiac disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePRV-015 in Phase 2 for celiac disease is a clear diversification move for Genmab A\/S, pushing it from oncology into a non-oncology autoimmune area. Celiac disease affects about 1% of people worldwide, or roughly 70 million patients, but most remain undiagnosed, so the unmet need is large. This is a new product for a new disease category, which adds both growth upside and clinical risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMim8 haemophilia A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003emim8’s Phase 2 move into haemophilia A is a diversification play for Genmab A\/S, taking it beyond its core oncology base into a rare bleeding disorder. Haemophilia A affects about 1 in 5,000 male births, so the market is smaller than cancer but can support premium pricing and long treatment cycles. Still, Phase 2 means clinical and regulatory risk remains high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLu AF82422 multiple system atrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLu AF82422 is in Phase 2 for multiple system atrophy, a rare neurodegenerative disease with no approved disease-modifying therapy. That move takes Genmab A\/S into a new market beyond oncology and hematology, broadening its R\u0026amp;D risk and revenue options. It also fits a diversification play by adding a high-unmet-need CNS program to a portfolio still anchored by cancer and blood disorder assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCureVac mRNA antibody products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab’s CureVac tie-up moves it into mRNA-based antibody products, which is a clear diversification step beyond classic antibody discovery. The deal gives Genmab access to a new platform for differentiated products and expands its technology base, not just its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMoves into new product space\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUses mRNA, not only antibodies\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBroadens future growth options\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eApproximately 20 pre-clinical programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab A\/S’s roughly 20 active pre-clinical programs widen its future entry points beyond today’s marketed portfolio. That gives the company several shots at new antibodies, targets, and indications, which lowers reliance on any one product. It also supports longer-term diversification as assets move into clinical testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~20 pre-clinical programs\u003c\/li\u003e\n\u003cli\u003eMore product entry points\u003c\/li\u003e\n\u003cli\u003eBroader indication spread\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab Broadens Beyond Oncology With New Pipeline Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S’s diversification push is real: PRV-015, mim8, and Lu AF82422 each enter new diseases outside oncology, while the CureVac deal adds an mRNA platform. Together, these moves spread risk across autoimmune, bleeding, and CNS markets. The pipeline now also includes about 20 pre-clinical programs, widening future entry points.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV-015\u003c\/td\u003e\n\u003ctd\u003eCeliac disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emim8\u003c\/td\u003e\n\u003ctd\u003eHaemophilia A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLu AF82422\u003c\/td\u003e\n\u003ctd\u003eMultiple system atrophy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234429378825,"sku":"gmab-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gmab-ansoff-matrix.webp?v=1785720032","url":"https:\/\/dcfanalyst.com\/products\/gmab-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}